Latest market price
44.25
-0.83-1.84%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.64 | Insider Own | 31.23% | Shs Outstand | 73.27M | Perf Week | 6.58% |
| Market Cap | 3.24B | Forward P/E | — | EPS next Y | -2.27 | Insider Trans | -6.09% | Shs Float | 46.78M | Perf Month | -4.24% |
| Enterprise Value | 2.35B | PEG | — | EPS next Q | -0.45 | Short Float | 19.95% | Perf Quarter | -23.76% | ||
| Income | -106.00M | P/S | — | EPS this Y | — | Short Ratio | 7.96 | Perf Half Y | 6.12% | ||
| Sales | 0.00 | P/B | 3.62 | EPS next Y | — | ROA | -11.64% | Short Interest | 9.33M | Perf YTD | 187.34% |
| Book/sh | 12.21 | P/C | 3.62 | EPS next 5Y | — | ROE | -18.55% | 52W High | 62.32 -29.00% | Perf Year | 95.36% |
| Cash/sh | 12.21 | P/FCF | — | EPS past 3/5Y | — | ROIC | -13.88% | 52W Low | 14.79 199.19% | Perf 3Y | 262.70% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.06% 4.29% | Perf 5Y | 209.87% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.87 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 64.07 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 51.03 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 64.07 | EPS Q/Q | 0.00% | SMA20 | 6.42% | Beta | 0.32 | Target Price | 76.29 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -9.14% | Rel Volume | 0.93 | Prev Close | 45.08 |
| Employees | 67 | LT Debt/Eq | 0.00 | Earnings | Nov 11 | SMA200 | 3.55% | Avg Volume | 1.34M | Price | 44.25 |
| IPO Date | Mar 12, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -26.56% — | Net Debt/EBITDA | — | Volume | 1,236,948 | Change | -1.84% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | HC Wainwright & Co. | Buy | $65 → $73 |
| Oct-02-26 | Reiterated | Morgan Stanley | $70 | |
| Aug-18-26 | Initiated | Barclays | Overweight | $78 |
| Aug-18-26 | Reiterated | Mizuho | Outperform | $62 → $73 |
| Aug-06-26 | Reiterated | Stifel Nicolaus | $80 → $82 | |
| Aug-06-26 | Reiterated | Guggenheim | Buy | $80 → $78 |
| Aug-06-26 | Reiterated | Goldman Sachs | Buy | $67 → $80 |
| Jul-21-26 | Reiterated | Goldman Sachs | Buy | $59 → $67 |
| Jul-09-26 | Reiterated | HC Wainwright & Co. | Buy | $39 → $65 |
| Jul-01-26 | Reiterated | Stifel Nicolaus | $60 → $80 |
Latest News· Times ET
Oct-19-26
Oct-19-2602:28AM
Oct-14-26
Oct-14-2604:30PM
Oct-07-26
Oct-07-2611:21AM
Oct-06-26
Oct-06-2604:05PM
10:20AM
Oct-02-26
Oct-02-2604:24AM
Sep-16-26
Sep-16-2606:31PM
Sep-03-26
09:48AM
Aug-31-26
Aug-31-2611:57PM
06:05PM
Aug-28-26
Aug-28-2604:12AM
Aug-18-26
Aug-18-2609:58AM
Aug-06-26
04:03AM
Company
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 35 | 34 | 24 | 19 | — | — | — | — | — | |
| Research and Development | 89 | 86 | 81 | 65 | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -124 | -120 | -105 | -84 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 19 | 16 | 16 | 12 | — | — | — | — | — | |
| Net Income Before Taxes | -106 | -104 | -89 | -72 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -106 | -104 | -89 | -72 | — | — | — | — | — | |
| Net Income From Continuing Operations | -106 | -104 | -89 | -72 | — | — | — | — | — | |
| Net Income | -106 | -104 | -89 | -72 | — | — | — | — | — | |
| EPS (Recurring) | -1.64 | -1.83 | -1.89 | -2.01 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.64 | -1.83 | -1.89 | -2.01 | — | — | — | — | — | |
| EPS (Diluted) | -1.64 | -1.83 | -1.89 | -2.01 | — | — | — | — | — | |
| EBITDA | -106 | -103 | -88 | -71 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 66 | 57 | 47 | 36 | — | — | — | — | — | |
| Market Capitalization | 2,921 | 878 | 1,058 | 498 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Oct 19 '26 | Sale | 38.48 | 6,018 | 231,546 | 38,000 | Oct 21 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Oct 19 '26 | Option Exercise | 2.48 | 5,000 | 12,400 | 30,000 | Oct 21 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Oct 19 '26 | Sale | 38.47 | 5,000 | 192,342 | 25,000 | Oct 21 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Oct 19 '26 | Option Exercise | 14.85 | 6,018 | 89,367 | 44,018 | Oct 21 |
| Garland J. Scott | Director | Oct 01 '26 | Option Exercise | 15.47 | 13,000 | 201,110 | 13,000 | Oct 05 |
| Garland J. Scott | Director | Oct 01 '26 | Sale | 46.67 | 13,000 | 606,719 | 0 | Oct 05 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sep 17 '26 | Sale | 50.35 | 5,000 | 251,754 | 25,000 | Sep 21 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sep 17 '26 | Sale | 50.35 | 6,018 | 303,002 | 38,000 | Sep 21 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sep 17 '26 | Option Exercise | 14.85 | 3,982 | 59,133 | 44,018 | Sep 21 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Sep 17 '26 | Option Exercise | 2.48 | 5,000 | 12,400 | 30,000 | Sep 21 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Aug 17 '26 | Sale | 58.58 | 6,018 | 352,551 | 40,036 | Aug 19 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 '26 | Option Exercise | 2.48 | 5,000 | 12,400 | 30,000 | Aug 19 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 '26 | Sale | 58.59 | 5,000 | 292,931 | 25,000 | Aug 19 |
| Derynck Mika K | Director | Aug 04 '26 | Option Exercise | 10.84 | 158,795 | 1,720,967 | 158,795 | Aug 06 |
| Derynck Mika K | Director | Aug 04 '26 | Sale | 60.21 | 158,795 | 9,561,587 | 0 | Aug 06 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.